These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26416857)

  • 1. Different Therapeutic Outcomes of Benznidazole and VNI Treatments in Different Genders in Mouse Experimental Models of Trypanosoma cruzi Infection.
    Guedes-da-Silva FH; Batista DG; da Silva CF; Meuser MB; Simões-Silva MR; de Araújo JS; Ferreira CG; Moreira OC; Britto C; Lepesheva GI; Soeiro Mde N
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7564-70. PubMed ID: 26416857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.
    Calvet CM; Choi JY; Thomas D; Suzuki B; Hirata K; Lostracco-Johnson S; de Mesquita LB; Nogueira A; Meuser-Batista M; Silva TA; Siqueira-Neto JL; Roush WR; de Souza Pereira MC; McKerrow JH; Podust LM
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006132. PubMed ID: 29281643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of combined therapy with amiodarone and low-dose benznidazole in a mouse model of chronic Trypanosoma cruzi infection.
    Barbosa JMC; Pedra-Rezende Y; Mata-Santos HA; Vilar-Pereira G; Melo TG; Ramos IP; Gibaldi D; Moreira OC; Nunes DF; Batista MM; Lannes-Vieira J; Daliry A; Salomão K
    Biomed Pharmacother; 2024 Jun; 175():116742. PubMed ID: 38754265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease.
    Assíria Fontes Martins T; de Figueiredo Diniz L; Mazzeti AL; da Silva do Nascimento ÁF; Caldas S; Caldas IS; de Andrade IM; Ribeiro I; Bahia MT
    PLoS One; 2015; 10(6):e0128707. PubMed ID: 26076455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Listen to what the animals say: a systematic review and meta-analysis of sterol 14-demethylase inhibitor efficacy for in vivo models of Trypanosoma cruzi infection.
    Bisio MMC; Jurado Medina LS; García-Bournissen F; Gulin JEN
    Parasitol Res; 2024 Jun; 123(6):248. PubMed ID: 38904688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agents.
    Suryadevara PK; Racherla KK; Olepu S; Norcross NR; Tatipaka HB; Arif JA; Planer JD; Lepesheva GI; Verlinde CL; Buckner FS; Gelb MH
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6492-9. PubMed ID: 24120539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.
    Calvet CM; Vieira DF; Choi JY; Kellar D; Cameron MD; Siqueira-Neto JL; Gut J; Johnston JB; Lin L; Khan S; McKerrow JH; Roush WR; Podust LM
    J Med Chem; 2014 Aug; 57(16):6989-7005. PubMed ID: 25101801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Planning new Trypanosoma cruzi CYP51 inhibitors using QSAR studies.
    de Oliveira PIC; de Santana Miranda PH; Lourenço EMG; de Santana Nogueira Silverio PS; Barbosa EG
    Mol Divers; 2021 Nov; 25(4):2219-2235. PubMed ID: 32557280
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Rial MS; Seremeta KP; Esteva MI; Búa J; Salomon CJ; Fichera LE
    Parasitology; 2021 Apr; 148(5):566-575. PubMed ID: 33298212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drug discovery strategies for the treatment of benznidazole-resistance in
    Murta SMF; Lemos Santana PA; Jacques Dit Lapierre TJW; Penteado AB; El Hajje M; Navarro Vinha TC; Liarte DB; de Souza ML; Goulart Trossini GH; de Oliveira Rezende Júnior C; de Oliveira RB; Ferreira RS
    Expert Opin Drug Discov; 2024 Jun; 19(6):741-753. PubMed ID: 38715393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships of novel
    Espinoza-Chávez RM; Oliveira Rezende Júnior C; de Souza ML; Pauli I; Valli M; Gomes Ferreira LL; Chelucci RC; Michelan-Duarte S; Krogh R; Romualdo da Silva FB; Cruz FC; de Oliveira AS; Andricopulo AD; Dias LC
    Future Med Chem; 2024 Feb; 16(3):253-269. PubMed ID: 38193294
    [No Abstract]   [Full Text] [Related]  

  • 12. Expanding the binding envelope of CYP51 inhibitors targeting Trypanosoma cruzi with 4-aminopyridyl-based sulfonamide derivatives.
    Vieira DF; Choi JY; Roush WR; Podust LM
    Chembiochem; 2014 May; 15(8):1111-20. PubMed ID: 24771705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status.
    Torchelsen FKVDS; Mazzeti AL; Mosqueira VCF
    Expert Opin Investig Drugs; 2024 Jun; 33(6):575-590. PubMed ID: 38686546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Novel Pyrazolone Phosphodiesterase Inhibitors in Experimental Mouse Models of Trypanosoma cruzi.
    de Araújo JS; França da Silva C; Batista DDGJ; Nefertiti A; Fiuza LFA; Fonseca-Berzal CR; Bernardino da Silva P; Batista MM; Sijm M; Kalejaiye TD; de Koning HP; Maes L; Sterk GJ; Leurs R; Soeiro MNC
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel ruthenium complexes as potential drugs for Chagas's disease: enzyme inhibition and in vitro/in vivo trypanocidal activity.
    Silva JJ; Guedes PM; Zottis A; Balliano TL; Nascimento Silva FO; França Lopes LG; Ellena J; Oliva G; Andricopulo AD; Franco DW; Silva JS
    Br J Pharmacol; 2010 May; 160(2):260-9. PubMed ID: 20105182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents.
    Buckner F; Yokoyama K; Lockman J; Aikenhead K; Ohkanda J; Sadilek M; Sebti S; Van Voorhis W; Hamilton A; Gelb MH
    Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15149-53. PubMed ID: 14657358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease.
    Liu Z; Ulrich vonBargen R; Kendricks AL; Wheeler K; Leão AC; Sankaranarayanan K; Dean DA; Kane SS; Hossain E; Pollet J; Bottazzi ME; Hotez PJ; Jones KM; McCall LI
    Nat Commun; 2023 Oct; 14(1):6769. PubMed ID: 37880260
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    de Araujo FF; Nagarkatti R; Mazzeti AL; Gonçalves KR; de Figueiredo Diniz L; Campos do Vale I; Martins-Filho OA; Debrabant A; Bahia MT; Teixeira-Carvalho A
    Front Immunol; 2023; 14():1340755. PubMed ID: 38283347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enteric nervous system regeneration and functional cure of experimental digestive Chagas disease with trypanocidal chemotherapy.
    Khan AA; Langston HC; Walsh L; Roscoe R; Jayawardhana S; Francisco AF; Taylor MC; McCann CJ; Kelly JM; Lewis MD
    Nat Commun; 2024 May; 15(1):4400. PubMed ID: 38782898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug screening and development cascade for Chagas disease: an update of in vitro and in vivo experimental models.
    Soeiro MNC; Sales-Junior PA; Pereira VRA; Vannier-Santos MA; Murta SMF; Sousa AS; Sangenis LHC; Moreno AMH; Boechat N; Branco FSC; Holetz FB; Ávila AR; Pereira MCS
    Mem Inst Oswaldo Cruz; 2024; 119():e240057. PubMed ID: 38958341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.